GlaxoSmithKline acquires two solid tumor cell therapies from Immatics for $50 million httpbit.ly2HGMZruÂpic.twitter.commpWoOiyZaY

GlaxoSmithKline acquires two solid tumor cell therapies from Immatics for $50 million http://bit.ly/2HGMZru pic.twitter.com/mpWoOiyZaY

05:56 EST 20 Feb 2020 | Pharmafile

GlaxoSmithKline acquires two solid tumor cell therapies from Immatics for $50 million http://bit.ly/2HGMZru  pic.twitter.com/mpWoOiyZaY

More From BioPortfolio on "GlaxoSmithKline acquires two solid tumor cell therapies from Immatics for $50 million http://bit.ly/2HGMZru pic.twitter.com/mpWoOiyZaY"